ECO Animal Health Group receives marketing authorisation from European Medicines Agency

AIVLOSIN IN PIGS

ECO Animal Health Group plc(LON:ECO) has announced that, as anticipated, a marketing authorisation has been received from the European Medicines Agency for the use of Aivlosin® 625 mg/g Water Soluble Granules for the treatment and metaphylaxis (disease control) of Mycoplasma hyopneumoniae in pigs.  

The Group had previously announced a positive opinion on 22nd May 2020 with the marketing authorisation expected within two months.

Mycoplasma hyopneumoniae is the most common primary pathogen in pig respiratory disease and is a key instigator of secondary bacterial and viral pathogens. The EU market accounts for approximately 15 per cent of the world’s swine market.

Aivlosin®, ECO’s patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.

Marc Loomes, ECO Animal Health Group CEO, commented: “We are very pleased that this marketing authorisation has been received after only one month and we look forward to offering Aivlosin® for the treatment of Mycoplasma infections in this important market. This further approval underlines the value of Aivlosin® for the safe and highly effective treatment of a range of diseases and infections.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    HUTCHMED showcases new oncology data at ASCO 2025

    HUTCHMED (China) Limited is set to unveil groundbreaking data on key cancer therapies at the 2025 ASCO Annual Meeting, highlighting promising advancements in NSCLC and solid tumors.

    Ilika launches £3.8m fundraise including £0.5m Retail Offer

    Ilika Plc has successfully closed its accelerated bookbuild, raising approximately £3.3 million to enhance solid-state battery technology and commercial growth.

    Nuformix raises £210,000 to advance NXP002 and US Orphan Drug Application

    Nuformix plc (LON:NFX) aims to raise £210,000 through a conditional placing to advance its NXP002 inhalation treatment for IPF and PPF.

    Likewise grants over 3.1m shares under 2025 SAYE scheme

    Likewise Group plc (LON:LIKE) has successfully closed its 2025 Save As You Earn Scheme, granting options to 69 employees on over 3.1 million shares.

    Zotefoams reports record £50.7m revenue in strong start to 2025

    Zotefoams Plc reports strong sales growth of 8% and record revenue for the first four months of 2025, showcasing a successful strategic pivot into key markets.

    Ilika announces £3.5m fundraise via Placing and Retail Offer

    Ilika Plc, a leader in solid-state battery technology, plans to raise approximately £3.0 million through a new share placing and a retail offer for shareholders.

      Search

      Search